Literature DB >> 12857557

Thrombophilic mutations are a main risk factor for placental abruption.

Fabio Facchinetti1, Luca Marozio, Elvira Grandone, Cristina Pizzi, Annibale Volpe, Chiara Benedetto.   

Abstract

BACKGROUND AND OBJECTIVES: The aim of the present study was to evaluate inherited thrombophilic factor V Leiden and factor II A20210 mutations in women presenting with abruption of a normally implanted placenta. DESIGN AND METHODS: In a multi-center, case-control study, 50 consecutive women requiring immediate delivery because of abruption of the placenta were enrolled. Inclusion criteria were: abruptio placentae requiring immediate delivery, normally implanted placenta, Caucasian ethnic background, parity <3, delivery performed at Institutions. Exclusion criteria were: history of thromboembolism, history of 2 or more spontaneous abortions, uterine leiomyomas with a diameter >5 cm, illicit drug abuse, premature rupture of membranes, multiple pregnancy. One hundred Caucasian women with uneventful pregnancies carried to term, matched for parity and age, served as controls.
RESULTS: Heterozygotes were found to be significantly more prevalent among women with abruptio placentae than among controls. The carriership of the FV Leiden mutation confers a OR of 9.12 (95% C.I.: 2.18-31.7; p=0.0005). Women carrying F II A20210 mutation have a OR of 12.25 (95% C.I.: 2.36-29.6; p=0.0004). No homozygotes or double heterozygotes were found. Twenty-three patients (46%) also met the criteria for a diagnosis of pre-eclampsia (PE). In such cases the prevalence of mutations (factor V: 6 cases, 26.1%; factor II: 5 cases, 21.7%) was similar to that in women without pre-eclampsia (factor V: 5 cases, 18.7%; factor II: 5 cases, 18.5%). INTERPRETATION AND
CONCLUSIONS: The presence of either of the above reported thrombophilic mutations represents a relevant risk factor for the occurrence of placental abruption in Caucasians. This risk is independent of the development of pre-eclampsia. Patients who have had dramatic abruption of a normally implanted placenta should undergo evaluation for the presence of genetic mutations of coagulation factors V and II.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857557

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

1.  Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy.

Authors:  H Chen; L Zhou; L Meng; M Liu; J Tan; L Gao; J Zhang
Journal:  Ir J Med Sci       Date:  2011-08-02       Impact factor: 1.568

2.  Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells.

Authors:  Rashmi Sood; Shawn Kalloway; Alan E Mast; Cecilia J Hillard; Hartmut Weiler
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

3.  The endothelial protein C receptor plays an essential role in the maintenance of pregnancy.

Authors:  Michelle M Castillo; Qiuhui Yang; Abril Solis Sigala; Dosia T McKinney; Min Zhan; Kristen L Chen; Jason A Jarzembowski; Rashmi Sood
Journal:  Sci Adv       Date:  2020-11-06       Impact factor: 14.136

4.  Low birthweight in relation to placental abruption and maternal thrombophilia status.

Authors:  Carl A Nath; Cande V Ananth; Celeste DeMarco; Anthony M Vintzileos
Journal:  Am J Obstet Gynecol       Date:  2008-01-14       Impact factor: 8.661

5.  The significance of genetic polymorphisms of factor V Leiden and prothrombin in the preeclamptic Polish women.

Authors:  Agnieszka Seremak-Mrozikiewicz; Krzysztof Drews; Ewa Wender-Ozegowska; Przemyslaw M Mrozikiewicz
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.